Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot PET Imaging Study of [89Zr]DFO-YS5 in Various Malignancies
NCT07664397Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FG-3180 in nerve sheath tumor, bladder cancer and solid tumor. Primary endpoints: Mean maximum standard uptake value at 8 days, Median intra-tumoral maximum standard uptake value at 8 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
FG-3180
03
Conditions
nerve sheath tumorbladder cancersolid tumor
Beyond the preview
Go deeper on NCT07664397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07664397.